Larotaxel

Summary

Larotaxel (CHEMBL4279455) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including urinary bladder neoplasm and pancreatic neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 8
• Chemistry: 831.9 Da · C45H53NO14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4279455
Name	Larotaxel
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6918260
Molecular formula	C45H53NO14
Molecular weight	831.9
InChIKey	DXOJIXGRFSHVKA-BZVZGCBYSA-N

SMILES: CC1=C2[C@H](C(=O)[C@]34C[C@H]3C[C@@H]5[C@]([C@H]4[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C6=CC=CC=C6)NC(=O)OC(C)(C)C)O)O)OC(=O)C7=CC=CC=C7)(CO5)OC(=O)C)OC(=O)C

IUPAC name: [(1S,2S,3R,4S,7R,9S,11R,13R,16S)-4,13-diacetyloxy-1-hydroxy-16-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-15,18,18-trimethyl-12-oxo-6-oxapentacyclo[12.3.1.03,11.04,7.09,11]octadec-14-en-2-yl] benzoate

Also known as: Larotaxel, XRP-9881, Xrp9881, XRP9881, LAROTAXEL

Patent coverage: 1,174 distinct patent families (2,863 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
urinary bladder neoplasm	3	MONDO:0004987	EFO:0000294
pancreatic neoplasm	3	MONDO:0021040	EFO:0003860
breast neoplasm	3	MONDO:0021100	EFO:0003869
neoplasm	1	MONDO:0005070	MONDO:0004992

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00081796	PHASE3	COMPLETED	Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
NCT00417209	PHASE3	COMPLETED	Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
NCT00625664	PHASE3	COMPLETED	Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
NCT00087958	PHASE2	COMPLETED	Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment
NCT00327743	PHASE1/PHASE2	COMPLETED	Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
NCT00386685	PHASE2	COMPLETED	XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
NCT00387907	PHASE2	COMPLETED	Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
NCT00485979	PHASE2	COMPLETED	Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).